Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$224.66 USD

224.66
1,906,786

-2.27 (-1.00%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $224.54 -0.12 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up

by Zacks Equity Research

Tempest aims to explore strategic alternatives for advancing pipeline studies that maximize shareholder value. Stock rises in after-hours trading.

Zacks Equity Research

Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?

by Zacks Equity Research

Jazz (JAZZ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JHSC

Sundeep Ganoria headshot

JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?

by Sundeep Ganoria

We advise investors to use the price dip in JAZZ stock as a buying opportunity despite the dynamic shifts in the regulatory landscape.

Supriyo Bose headshot

5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath

by Supriyo Bose

ANET, GLW, JAZZ, AES and PPC are some of the stocks with high ROE to profit from as markets recoiled on tariff war.

Zacks Equity Research

AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs

by Zacks Equity Research

The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.

Zacks Equity Research

Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JHSC

Zacks Equity Research

AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication

by Zacks Equity Research

The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.

Zacks Equity Research

SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases

by Zacks Equity Research

The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.

Zacks Equity Research

AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol

by Zacks Equity Research

Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.